Viatris Inc. (NASDAQ:VTRS ) 43rd Annual J.P. Morgan Healthcare Conference 2025 January 14, 2025 11:15 AM ET Company Participants Scott Smith - CEO Doretta Mistras - CFO Philippe Martin - Chief R&D Off...

We have rated Viatris in the "neutral/hold" category since 2021. Over this time, the stock has lagged Treasury bills, despite sporting a high double digit "free cash flow yield". We tell you why that ...

Viatris said on Monday it has received a warning letter from the U.S. Food and Drug Administration after an inspection at its oral finished dose manufacturing facility in Indore, India earlier this ye...

Generic and biosimilar drugs are often preferred over the brand name version due to their cheaper prices. Generics are exact duplicates of the branded counterparts, while biosimilars are "similar" and...

Britain's competition watchdog fined U.S. firm Viatris 1.5 million pounds ($1.88 million) on Friday for violating an order during its investigation into Theramex's acquisition of European rights to tw...

Viatris Inc. (NASDAQ:VTRS ) Jefferies London Healthcare Conference Transcript November 21, 2024 5:30 AM ET Company Participants Scott Smith - Chief Executive Officer Doretta Mistras - Chief Financial ...

Viatris Inc. (NASDAQ:VTRS ) UBS Global Healthcare Conference November 12, 2024 11:45 AM ET Company Participants Doretta Mistras - CFO Conference Call Participants Ashwani Verma - UBS Ashwani Verma Goo...

Bargain Priced Viatris Reports Strong Q3 Earnings Results

Viatris Inc. VTRS reported third-quarter 2024 total net sales of $3.74 billion. That's down 5%, beating the consensus of $3.71 billion, but up about 3% on a divestiture-adjusted operational basis comp...

VTRS Q3 earnings and sales beat estimates. New products perform well.

Viatris Inc. (NASDAQ:VTRS ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - CEO Philippe Martin - Chief R&D Of...

While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compa...

Viatris (VTRS) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.78 per share a year ago.

Drugmaker Viatris beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares up 2....

Let us look at five large biotech and generic drug companies, NVO, GILD, MRNA, VTRS and TEVA, which are gearing up for their earnings releases this week.

Besides Wall Street's top -and-bottom-line estimates for Viatris (VTRS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the qu...

Viatris Inc. stock has experienced significant volatility since its 2020 inception, driven by disappointing early performance, asset sales, and fluctuating market expectations. Despite low P/E and P/S...